Semaglutide + Glycine
Compounded semaglutide with glycine as a sterile injectable. A GLP-1 receptor agonist used with diet and activity for weight and glucose support.12
Compounding required for medical necessity.
- Active ingredients
- Semaglutide
- Form
- Injection
- Route
- Subcutaneous
Are you a prescriber?
Download a compounding order form for this medication with dose options and packaging choices.
Semaglutide is a GLP-1 receptor agonist. STEP 1 demonstrated that once-weekly semaglutide with lifestyle intervention produced sustained weight reduction versus placebo in adults with overweight or obesity.1
Approved semaglutide labeling describes use with a reduced-calorie diet and increased physical activity, and includes a boxed warning regarding thyroid C-cell tumors in rodents.2
This formulation includes glycine, a conditionally essential amino acid involved in pathways such as glutathione synthesis.4 Glycine is being studied for metabolic roles relevant to obesity and related conditions; lower circulating glycine levels are observed in those settings.3 That literature does not establish that adding glycine makes this compounded product more effective than semaglutide alone for weight or glucose control.
Compounded as a sterile injectable for patient-specific prescriptions when medically necessary. It is not an FDA-approved finished drug. Prescribers individualize dosing and follow-up. Discuss gastrointestinal tolerability, contraindications (including MTC/MEN2 history), and monitoring needs with your clinician.
References
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989-1002
“In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.”
- U.S. Food and Drug Administration (2025). WEGOVY (semaglutide) injection, for subcutaneous use — Prescribing Information. FDA Prescribing Information
- Alves A et al. (2019). Glycine Metabolism and Its Alterations in Obesity and Metabolic Diseases. Nutrients, 11, 1356
“In metabolic disorders associated with obesity, type 2 diabetes, and non-alcoholic fatty liver disease, lower circulating glycine levels have been consistently observed.”
- Wang W et al. (2013). Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids, 45, 463-477